$1.46
9.03% yesterday
NYSE, Apr 04, 10:00 pm CET
ISIN
US20454B1044
Symbol
CMPX
Sector
Industry

Compass Therapeutics Stock price

$1.46
-1.32 47.48% 1M
-0.47 24.35% 6M
+0.01 0.69% YTD
-0.28 16.09% 1Y
-0.14 8.75% 3Y
-7.04 82.82% 5Y
-7.04 82.82% 10Y
NYSE, Closing price Fri, Apr 04 2025
-0.15 9.03%
ISIN
US20454B1044
Symbol
CMPX
Sector
Industry

Key metrics

Market capitalization $201.89m
Enterprise Value $81.80m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 96.24
P/S ratio (TTM) P/S ratio 237.52
P/B ratio (TTM) P/B ratio 1.61
Revenue (TTM) Revenue $850.00k
EBIT (operating result TTM) EBIT $-56.62m
Free Cash Flow (TTM) Free Cash Flow $-44.90m
Cash position $126.72m
EPS (TTM) EPS $-0.36
P/E forward negative
Short interest 4.70%
Show more

Is Compass Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Compass Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Compass Therapeutics forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Compass Therapeutics forecast:

Buy
100%

Financial data from Compass Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.85 0.85
-
100%
- Direct Costs 1.75 1.75
7% 7%
206%
-0.90 -0.90
52% 52%
-106%
- Selling and Administrative Expenses 12 12
33% 33%
1,436%
- Research and Development Expense 42 42
12% 12%
4,912%
-55 -55
13% 13%
-6,455%
- Depreciation and Amortization 1.75 1.75
7% 7%
206%
EBIT (Operating Income) EBIT -57 -57
12% 12%
-6,662%
Net Profit -49 -49
16% 16%
-5,808%

In millions USD.

Don't miss a Thing! We will send you all news about Compass Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Compass Therapeutics Stock News

Neutral
GlobeNewsWire
2 days ago
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025.
Neutral
GlobeNewsWire
4 days ago
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significa...
Neutral
GlobeNewsWire
4 days ago
Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data...
More Compass Therapeutics News

Company Profile

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Head office United States
CEO Thomas Schuetz
Employees 35
Founded 2014
Website www.compasstherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today